2/24
07:01 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/2
08:05 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
1/30
08:02 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
1/21
06:34 am
smmt
Crescent Biopharma initiated with a Buy at Guggenheim
Medium
Report
Crescent Biopharma initiated with a Buy at Guggenheim
1/21
06:34 am
smmt
Crescent Biopharma initiated with a Buy at Guggenheim
Medium
Report
Crescent Biopharma initiated with a Buy at Guggenheim
1/14
08:42 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/17
09:44 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
12/17
09:44 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
12/17
09:12 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.
12/17
05:40 am
smmt
Summit Therapeutics upgraded to Equal Weight from Underweight at Barclays
Low
Report
Summit Therapeutics upgraded to Equal Weight from Underweight at Barclays
12/17
05:40 am
smmt
Summit Therapeutics upgraded to Equal Weight from Underweight at Barclays
Low
Report
Summit Therapeutics upgraded to Equal Weight from Underweight at Barclays